MCM
CORT icon

Moore Capital Management’s Corcept Therapeutics CORT Stock Holding History

Moore Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$1.18M – 229
2017
Q2 		$1.18M Buy
+100,000
New +$1.09M 0.04% 152

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Moore Capital Management's CORT Position: Q3 2017 in Review

Moore Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2017, closing a stake of 100,000 shares — an estimated $1.18M sold.

Moore Capital Management first reported a position in CORT in Q2 2017 and held it in 1 quarter. The position peaked at $1.18M in Q2 2017. 189 funds tracked by Wall St. Rank hold CORT as of Q3 2017.

  • Moore Capital Management reported no remaining Corcept Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Moore Capital Management sold 100,000 Corcept Therapeutics shares in Q3 2017, an estimated $1.18M.
  • Moore Capital Management first reported a position in Corcept Therapeutics in Q2 2017 and held it in 1 quarter.
  • Moore Capital Management's Corcept Therapeutics position peaked at $1.18M in Q2 2017.
  • 189 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2017.

Based on Moore Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.